Clinical Trials Browser

Phase 2 × Pharmacogenomic Variants × Clear all

NCT03506373 2026-03-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Waldenstrom Macroglobulinemia

NCT03698994 2025-12-03

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Phase 2 Active not recruiting

20 enrolled 9 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03300557 2025-08-29

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Phase 2 Completed

40 enrolled 13 charts

Endometrial Hyperplasia, Endometrial Neoplasms

NCT03370718 2024-12-10

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Phase 2 Completed

18 enrolled 5 charts

Adrenal Cortex Neoplasms

NCT03477396 2024-02-20

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

2 enrolled 13 charts

Estrogen Receptor and/or Progesterone Receptor Positive

NCT03520842 2023-08-01

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Phase 2 Completed

22 enrolled 20 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03557970 2021-12-02

JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Terminated

3 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute